NeuroNEXT

Ka-Ho Wong, Gregory Scott Day, James C. Torner, Merit Cudkowicz, Christopher S. Coffey, Hyun Joo Sophie Cho, Ursula Utz, David B. Clifford, Eliezer Katz, John Ratchford, Susan Flavin, Annalisa Dialino-Felix, Lisa M. Dill, Cornelia Kamp, Eric C. Klawiter, John Robinson Singleton, Janel Fedler, Elizabeth A. Klingner, Dixie Ecklund, David Klements, Michele Costigan, Erin Steinhart, Brenda Pearson, Christina Desir, Josep O. Dalmau, Maarten J. Titulaer, and Stacey L. Clardy

A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial

Hyun Joo Sophie Cho, MD, Chris Boshoff, PhD, Shantadurga Rajaram, PhD, and Clinton B. Wright, MD, MS

Moving Things Along: A New Model for the NINDS Clinical Neurotherapeutic Pipeline

Dragana Protic , Elizabeth Breeze, Guadalupe Mendoza, Marwa Zafarullah, Leonard Abbeduto, Randi Hagerman, Christopher Coffey, Merit Cudkowicz, Blythe Durbin-Johnson, Paul Ashwood, Elizabeth Berry-Kravis, Craig A Erickson, Robin Filipink, Andrea Gropman, Lenora Lehwald, Angela Maxwell-Horn, Stephanie Morris, Amanda Palladino Bennett, Lisa Prock, Amy Talboy, Nicole Tartaglia, Jeremy Veenstra-VanderWeele2, and Flora Tassone

Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome

Smith AG, Singleton JR, Aperghis A, Coffey CS, Creigh P, Cudkowicz M, Conwit R, Ecklund D, Fedler JK, Gudjonsdottir A, Hauer P, Herrmann DN, Kearney M, Kissel J, Klingner E, Quick A, Revere C, Stino A; NeuroNEXT NN108 TopCSPN Study Team

Safety and Efficacy of Topiramate in Individuals With Cryptogenic Sensory Peripheral Neuropathy With Metabolic Syndrome: The TopCSPN Randomized Clinical Trial

Berry-Kravis E, Abbeduto L, Hagerman R, Coffey CS, Cudkowicz M, Erickson CA, McDuffie A, Hessl D, Ethridge L, Tassone F, Kaufmann WE, Friedmann K, Bullard L, Hoffmann A, Veenstra-VanderWeele J, Staley K, Klements D, Moshinsky M, Harkey B, Long J, Fedler J, Klingner E, Ecklund D, Costigan M, Huff T, Pearson B; NeuroNEXT FXLEARN Investigators

Effects of AFQ056 on language learning in fragile X syndrome

Griguer CE, Oliva CR, Coffey CS, Cudkowicz ME, Conwit RA, Gudjonsdottir AL, Ecklund DJ, Fedler JK, Neill-Hudson TM, Nabors LB, Benge M, Hackney JR, Chase M, Leonard TP, Patel T, Colman H, de la Fuente M, Chaudhary R, Marder K, Kreisl T, Mohile N, Chheda MG, McNeill K, Kumthekar P, Dogan A, Drappatz J, Puduvalli V, Kowalska A, Graber J, Gerstner E, Clark S, Salacz M, Markert J

Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial

Lowenhaupt, Stephanie; Malloy, Angela

Virtual coordinator and site training and reorganization of a multisite consortium upon grant renewal: Challenges of the NeuroNEXT network

Carillo N, Malicdan MC, Leoyklang P, Shrader JA, Joe G, Slota C, Perreault J, Heiss JD, Class B, Liu CY, Bradley K, Jodarski C, Ciccone C, Driscoll C, Parks R, Van Wart S, Bayman L, Coffey CS, Quintana M, Berry SM, Huizing M, and Gahl WA

Safety and Efficacy of N-Acetylmannosamine (ManNAc) in Patients with GNE Myopathy: An Open-Label Phase 2 Study

Ken Sakaie, Janel K Fedler, Jon W Yankey, Kunio Nakamura, Josef Debbins, Mark J Lowe, Paolo Raska, Robert J Fox

Influence of equipment changes on MRI measures of brain atrophy and brain microstructure in a placebo-controlled trial of ibudilast in progressive multiple sclerosis

Naismith RT, Bernel RA, Coffey CS, Goodman AD, Fedler JK, Chase M, Klawiter EC, Nakamura K, Narayanan S, Goebel C, Yankey JW, Klingner EA, Fox RJ.

Effects of Ibudilast on MRI measures in the Phase 2 SPRINT-MS Study